PATL2

Across TCGA pan-cancer cohorts, PATL2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PATL2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PATL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PATL2 is over-expressed in tumor, although a few such as LUSC and BRCA show the opposite, repressed pattern.

KIRC, KICH, and LUSC are the cancer types where PATL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PATL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.748	<.001	11	view →
KICH	Female	III,IV	+1.096	<.001	8	view →
LUSC	All	II,III,IV	−0.659	<.001	8	view →
STAD	All	II,III,IV	+0.718	<.001	7	view →
KIRP	Male	All	+0.445	<.001	7	view →
HNSC	All	All	+0.248	.006	6	view →
ESCA	All	II,III,IV	+1.265	.043	2	view →
BRCA	All	III,IV	−0.178	.046	2	view →
COAD	Female	All	−0.201	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PATL2–KIRC

Open the KIRC breakdown →